Galapagos NV

GXE

Company Profile

  • Business description

    Galapagos NV is a fully integrated biotechnology company with operations in Europe and the United States, dedicated to developing medicines focusing on oncology and immunology. The group focuses on unmet medical needs, it synergizes compelling science, technology, and collaborative approaches to create a deep pipeline of medicines. Its clinical pipeline includes: GLPG5101, a CD19 CAR-T product candidate decentralized manufactured, currently in Phase 1/2 in rrNHL; GLPG5301, a BCMA CAR-T product candidate decentralized manufactured, currently in Phase 1 in rrMM; and GLPG3667, a TYK2 inhibitor currently in Phase 2 clinical trial in DM and SLE. It derives maximum revenue from the United States of America.

  • Contact

    Generaal De Wittelaan L11 A3
    Mechelen2800
    BEL

    T: +32 15342900

    E: [email protected]

    https://www.glpg.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2025

    Employees

    704

Stocks News & Analysis

stocks

A collection of our best stock opportunities

Our latest articles about where we see opportunities in the market.
stocks

Morningstar analyst reacts to Macquarie Group’s earnings

Banking Analyst Nathan Zaia’s analysis of MQG’s results.
stocks

Undervalued ASX share showing progress in global efforts

More clarity on the path forward in the UK.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,963.5029.200.33%
CAC 407,925.5490.961.16%
DAX 4024,436.09218.590.90%
Dow JONES (US)44,901.92208.010.47%
FTSE 1009,164.8544.540.49%
HKSE25,588.18199.830.79%
NASDAQ21,108.3250.360.24%
Nikkei 22540,998.27457.96-1.10%
NZX 50 Index12,910.7457.280.45%
S&P 5006,388.6425.290.40%
S&P/ASX 2008,697.7030.800.36%
SSE Composite Index3,597.944.280.12%

Market Movers